Where Ideas grow

1st Symposium on
Oligonucleotide Technologies and Therapeutics@Portugal – OTP2021

8-9 July 2021 | ONLINE EVENT

 

To avoid any uncertainty in the COVID situation it has been decided that the 1st OTP will go fully ONLINE. We hope to resume in-person meeting on the next occasion.

 

 

The first Symposium on Oligonucleotide Technologies and Therapeutics in Portugal (OTP2021) wants to bring together national and international scientists from academia and industry, as well as the medical community, interested in nucleic-acids-based technologies and therapeutics. We expect to cover a wide range of topics in different sessions dedicated to:

I- Nucleic Acids Chemistry, Structures and Technologies
II- Delivery and Targeting
III- Discovery and Development (pre-clinical and clinical)

We aim to contribute to the creation of a network and forum by gathering national young and established scientists in the country, both from academia and industry, together with leading international guest speakers. We encourage you to take this opportunity to discuss your research and to submit your abstract for a poster presentation.

Organization

Organizing Committee
Pedro Moreno (INEB/i3S)
Sofia Santos (INEB/i3S)
Nuno Azevedo (FEUP, LEPABE)
Rita Sobral Santos (FEUP, LEPABE)
Nuno Guimarães (FEUP, LEPABE)
Sandra Alves (Instituto Nacional de Saúde Dr. Ricardo Jorge/CECA-ICETA)
Liliana Matos (Instituto Nacional de Saúde Dr. Ricardo Jorge/CECA-ICETA)
Daniel Vasconcelos (University of Porto, Faculty of Medicine, Biomedicine department)

 

Scientific Committee
Pedro Moreno (INEB/i3S)
Sofia Santos (INEB/i3S)
Ana P. Pêgo (INEB/i3S)
Nuno Azevedo (FEUP, LEPABE)
Rita Sobral Santos (FEUP, LEPABE)
Nuno Guimarães (FEUP, LEPABE)
Sandra Alves (Instituto Nacional de Saúde Dr. Ricardo Jorge/CECA-ICETA)
Liliana Matos (Instituto Nacional de Saúde Dr. Ricardo Jorge/CECA-ICETA)
Daniel Vasconcelos (University of Porto, Faculty of Medicine, Biomedicine department)
Bruno Godinho (UMass, RNA Institute, USA)

 

Program

DAY 1 | 8 JULY 2021

 

10:30 – 10:45 Login Start 

10:45 – 11:00 Welcome note 

 

Session I – Nucleic acids chemistry, structures and technologies 

Synthesis and modifications of nucleoside, nucleotides and oligonucleotides; conjugates; DNA/RNA nanotechnology; aptamers; sensors/diagnostics. 

 

11:00 – 11:30 Jorgen Kjems, iNANO, Arrhus University, DK 

11:30 – 12:00 Marcel Hollenstein, Institut Pasteur, FR 

12:00 – 13:00 Lunch Break  

13:00 – 15:00 Poster Session / Networking  

 

15:00 – 15:30 Muthiah Manoharan, Alnylam Pharmaceuticals, USA 

15:30 – 16:00 Nuno M. Xavier, Univ. Lisboa, PT 

16:00 – 16:30 Carina Almeida, INIAV, PT 

16:30 – 17:00 Coffee break  

 

Session II – Delivery and Targeting 

Mammalian and bacterial cell uptake; nanoparticle-based delivery; conjugate-based delivery; tissue targeting; intracellular trafficking. 

 

17:00 – 17:30 Stefaan De Smedt, Univ. Gent, BE 

17:30 – 18:00 Steven Dowdy, Univ. California, San Diego School of Medicine, USA 

 


 

DAY 2 | 9 JULY 2021

 

Continuation, Session II – Delivery and Targeting 

09:30 – 10:00 Ana P. Pêgo, i3S, Univ. Porto, PT 

10:00 – 10:30 João Gonçalves, iMed-Univ.Lisboa, PT 

10:30 – 11:00 Coffee break  

 

Session III – Discovery and Development 

11:00 – 11:30 Lourdes Ruiz Desviat, Universidad Autónoma de Madrid, ES 

11:30 – 12:00 Luís Almeida, CNC, Univ.Coimbra, PT 

12:00 – 13:00 Lunch break  

13:00 – 15:00 Poster Session / Networking 

 

15:00 – 15:30 Sónia Silva, CEB , UMinho, PT 

15:30 – 16:00 Aurélie Goyenvalle, University of Versailles, FR 

16:00 – 16:30 Brett P. Monia, IONIS Pharmaceuticals, USA 

16:30 – 16:45 Coffee break  

 

16:45 – 17:15 Teresa Coelho, Hospital Sto António, Centro Hospitalar do Porto, PT 

17:15 – 17:30 Closing note  

Speakers

Confirmed speakers:

SESSION I - Nucleic Acids Chemistry, Structures and Technologies

Muthiah (Mano) Manoharan 

Senior Vice President of Drug Innovation Chemistry, Scientific Advisory Board Member, and Distinguished Research Scientist at Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.

Dr. Muthiah (Mano) Manoharan serves as  the Senior Vice President of Drug Innovation Chemistry, a  Scientific Advisory Board Member, and a Distinguished Research Scientist at Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA. Dr. Manoharan has had a distinguished career as a world-leading chemist in the areas of oligonucleotide chemical modifications, conjugation chemistry, and delivery platforms (lipid nanoparticles (LNPs), polymer conjugates, and complex-forming strategies).  Dr. Manoharan and his research group designed, synthesized and demonstrated for the first time the human therapeutic applications of GalNAc-conjugated oligonucleotides at Alnylam, a platform that has revolutionized the nucleic acid-based therapeutics field with several compounds presently in the advanced clinical trials.   Under his leadership, the Alnylam team developed the ionizable lipid nanoparticles (LNPs), the formulation for ONPATTRO (patisiran), the first RNAi therapeutic approved by FDA. ONPATTRO was approved in 2018 for treating TTR amyloidosis-mediated polyneuropathy. The GalNAc platform has been validated by the first clinically approved GalNAc-siRNA conjugate, GIVLAARI (givosiran), was approved for the treatment of acute hepatic porphyria by the FDA in November 2019. 
 
Prior to Alnylam, Dr. Manoharan worked at Ionis  (formerly Isis) Pharmaceuticals and  LifeCodes Corporation in the field of antisense oligonucleotide therapeutics. He is an author of more than 215 publications (nearly 43,000 Google Scholar citations with an h-index of 94 and an i10-index of 380) and over 400 abstracts, as well as an inventor of over 245 issued U.S. patents.  
Dr. Manoharan has been recognized as the Lifetime Achievement Awardee of the Oligonucleotide Therapeutics Society for the year 2019.  He received the M. L. Wolfrom Award from the American Chemical Society in 2007.
 


Marcel Hollenstein

Coordinator of Bioorganic Chemistry of Nucleic Acids Group, Institut Pasteur, Paris, France

 


Nuno M. Xavier

Assistant Researcher at Centro de Química Estrutural (CQE), Faculty of Sciences, University of Lisbon (FCUL), Portugal

Nuno M. Xavier (b. Nov. 1982, Vila Real, Portugal) is a Researcher at Centro de Química Estrutural (CQE), Faculty of Sciences, University of Lisbon (FCUL). He was awarded a double PhD degree in Chemistry (Organic Chemistry) from the University of Lisbon and from the National Institute of Applied Sciences of Lyon in 2011. He was afterwards a Postdoctoral Research Fellow at the University of Natural Resources and Life Sciences of Vienna and then at FCUL. In 2014 he was awarded an Investigator Starting Grant at FCUL and recently he has been selected as Assistant Researcher at CQE, the both of which under highly competitive calls from the Portuguese Foundation for Science and Technology (FCT). His research has been devoted to the development of efficient synthetic methodologies for novel bioactive carbohydrate-based molecules, for which he has been internationally recognized with various Young Scientist Awards (e.g. IUPAC, Alberta Ingenuity Centre for Carbohydrate Science - Canada, Groupe Lyonnais des Glyco-Sciences - France) and an Innovation Award at the International Carbohydrate Symposium 2018. He has been particularly focused on nucleoside and nucleotide chemistry towards new molecules of potential therapeutic application. He was the PI of an FCT-funded R&D exploratory project and Team Member of 8 projects funded by national or international entities. He has acted as Guest Editor for Pharmaceuticals and Frontiers in Chemistry (Section “Medicinal and Pharmaceutical Chemistry”) and as Topic Editor for Frontiers in Chemistry and Antibiotics. His research activities have been reported in ca. 40 publications and he has been Speaker of more than 30 lectures in international and national Symposia. 

 


Carina Almeida

Associate Researcher of the National Institute of Agrarian and Veterinary Research (INIAV), Portugal. Co-founder of Biomode S.A.

 


Jorgen Kjems

Professor, Interdisciplinary Nanoscience Centre (iNANO), Department of Molecular Biology and Genetics, Aarhus University, Denmark

 


SESSION II - Delivery and Targeting

 

Steven F. Dowdy

Professor, Univ. of California San Diego, School of Medicine, USA. Board member of Oligonucleotide Therapeutics Society

Professor Steven Dowdy, from University of California San Diego School of Medicine, has focused his research on the delivery of novel therapeutics into cells, especially RNAi therapies. He is the founder and serves on the Scientific Advisory Boards of several Biotech companies and is a member of the Board of Directors of the Oligonucleotide Therapeutics Society. He is a co-author of more than 100 peer-reviewed high impact publications in cell and molecular medicine.

 


Stefaan De Smedt

Professor, University of Ghent, Belgium. Pro-dean of the faculty of Pharmaceutical Sciences, Director of Ghent Research Group on Nanomedicines, Director of Laboratory of General Biochemistry and Physical Pharmacy

Stefaan C. De Smedt  (°1967) studied pharmacy and graduated from Ghent University (Belgium). In 1995 he joined the pharmaceutical development group of Janssen Research Foundation and became Professor in Physical Pharmacy and Biopharmacy at Ghent University (1999) where he initiated his research on advanced delivery of biologics/nanomedicines and founded the Ghent Research Group on Nanomedicines. He served as dean of the Faculty of Pharmaceutical Sciences at Ghent University from 2010 till 2014. Since 2014 he is a member of the Board of Directors of Ghent University. He has been a Guest Professor at the Catholic University of Leuven (Belgium),  the University of Antwerp (Belgium) and the Shanghai Jiao Tong University (China). He is a Distinguished Visiting Scientist of the Chinese Academy of Sciences at the University of Science and Technology of China (Hefei; 2017), and Specially Appointed Professor of Nanjing Foresty University (2016-2019). Since 2004 he serves as the European Associate Editor of the Journal of Controlled Release (JCR); in 2015 he became Editor of JCR for the regions Europe- the Middle East & Africa. Since 2020 he is Deputy Editor in Chief of JCR.

Research of Prof. de Smedt is at the interface between drug delivery, biophysics, material sciences and physical chemistry. He is the author or co-author of about 350 manuscripts (h-factor: 68; > 17500 citations) including contributions to Nature Materials, Nature Communications, Nature biotechnology, Nature Drug Discovery Reviews, Nano Letters, … In 2018 he became awarded Highly Cited Researcher (interdisciplinary sciences) by Web of Science (Thomson Reuters).  He has been the scientific (co-)promoter and mentor of 48 defended doctoral thesis’s; 8 of his doctoral/post-doctoral fellows are assistant/associate/full professors at various faculties; three of them received most prestigious Starting / Consolidator Grants from the European Research Council (ERC). 

Dr. S.C. De Smedt received the Scott Blair Biorheology Award for his Ph.D work; For his research on drug delivery he received the Controlled Release Society Young Investigator Award 2006 (Vienna) and the APV Research Award 2010 for Outstanding Research Achievements in Pharmaceutical Sciences (Malta). In 2015 he was awarded as member of the Belgian Royal Academy of Medicine. In 2016 he and his co-worker Dr. Koen Raemdonck received the T. Nagai Research Achievement Award (Seattle). In 2017 he was awarded as Distinguished Scientist of the Chinese Academy of Sciences  (Hefei).

Dr. De Smedt filed 20 patents on carriers (and adjuvants) for drug delivery, and materials (and methods) for diagnostics.  He is a scientific founder of Memobead Technologies, a spin-off from Ghent University, whose technology was further developed by Biocartis in Lausanne (Swiss) and Mechelen (Belgium). Currently MyCartis (Ghent) commercializes the technology. Dr. De Smedt is a member of the Drug Delivery Advisory Panel of Santen (Japan) specialized in ophthalmological medicines.

Dr. De Smedt is as member of the Belgian Royal Academy of Medicine (elected 2015), the European Academy of Sciences (section medicine & life sciences; elected 2018) and the Académie Nationale de Pharmacie of France (elected 2019). 

 


Ana P. Pêgo

Coordinator of the nBTT - nanoBiomaterials for Targeted Therapies Group at i3S - Instituto de investigação e Inovação em Saúde, Universidade do Porto, Portugal

Ana Paula Pêgo got her Ph.D. in Polymer Chemistry and Biomaterials from the University of Twente, the Netherlands, in 2002. In 2003 she moved to INEB – Instituto de Engenharia Biomédica, where she became a Principal Investigator in 2012. In 2015, INEB joined the i3S – Instituto de Investigação e Inovação em Saúde (Universidade do Porto), where Ana Paula Pêgo leads the nanoBiomaterials for Targeted Therapies (nBTT) Group.
By using nanomedicine strategies the nBTT Group, aims at providing in situ and in a targeted manner the required signals to promote nervous tissue regeneration. The research on new biomaterials for application in neurosciences includes the development of new polymers for the design of alternative vectors to viruses for efficient nucleic acid delivery and preparation of nerve grafts for spinal cord injury treatment. Societal and ethical issues that concern Regenerative Medicine and NanoMedicine are also topics in which Ana Pêgo is involved.
She has been appointed the Scientific Director of the Bioimaging Centre for Biomaterials and Regenerative Therapies of INEB and she is an Invited Associate Professor at the Instituto de Ciências Biomédicas Abel Salazar (ICBAS) and at the Faculty of Engineering (FEUP) of the University of Porto.
Currently, Ana Paula Pêgo is a member of the Board of Directors of i3S, serves as an Associate Editor of Biomaterials (Elsevier) and is the Secretary of the Council of the European Society for Biomaterials.
 


João Gonçalves

Head of the Biopharmaceutical and Molecular Biotechnology Unit at the iMed-Research Institute for Medicines and Pharmaceutical Sciences, Faculty of Pharmacy, University of Lisbon, Portugal.

Joao Goncalves is Head of the Biopharmaceutical and Molecular Biotechnology Unit at the iMed-Research Institute for Medicines and Pharmaceutical Sciences and Professor of Immunology and Biotechnology both part of the Faculty of Pharmacy, University of Lisbon, Portugal. He is also Head of Antibody Engineering Laboratory at iMed – Faculdade Farmacia Universidade Lisboa. Professor Joao Goncalves has a pharmaceutical degree and PhD in Infectious Diseases/Immunology. He has postdoctoral experience at Harvard University and Scripps Research Institute, La Jolla. His research focuses on therapeutic antibody discovery and development ranging from virology to oncology. His group is interested in biomolecular and biopharmaceutical engineering aiming the investigation, analysis and integration of genomic and proteomic data towards the design of therapeutic proteins. This will lead us to guide protein engineering through molecular medicine and bio-nanotechnology in a mid- to long-term timeframe. At the center of our biopharmaceutical development, we aim at rational antibody engineering as our approach to validating our theoretical concepts. We consider the use of intracellular and extracellular small-domain antibodies to be exemplary in our rational protein engineering strategies. We have applied our stability engineering strategies to the construction of hyper-stable and effective small antibodies. 
The focus on the discovery and development of a new class of therapeutic antibodies and efficient display technologies may allow the rapid identification of binding proteins with high affinity and specificity. The domain antibodies combine the advantages of conventional antibodies with the benefits of small-molecule drugs. 
 

 


SESSION III - Discovery and Development

 

Brett P. Monia

CEO, IONIS Pharmaceuticals, USA

Dr. Monia is the chief executive officer, a member of the board of directors and a founding scientist of Ionis Pharmaceuticals. His contributions at Ionis include research into the medicinal chemistry and mechanisms of action of RNA-targeting modalities to treat human diseases, most notably antisense-based therapeutic strategies. Dr. Monia has extensive experience across a range of therapeutic areas, including oncology, metabolic disease, inflammation, neurological disease and cardiovascular disease, which have resulted in a broad range of successful clinical achievements and in marketing approvals for new medicines.
 
Dr. Monia has published more than 200 primary research manuscripts, reviews and book chapters, and is an inventor on more than 100 issued patents. He serves as a senior editor for the journal Nucleic Acid Therapeutics. He is on the board of directors of Cognition Therapeutics and Dynacure. He has also served as president of the Oligonucleotide Therapeutics Society (OTS). Dr. Monia is an adjunct professor of biology at San Diego State University where he lectures at the graduate level on pharmacology.
 
Dr. Monia received his Ph.D. in Pharmacology at the University of Pennsylvania and B.S. degrees in Molecular Biology and Analytical Chemistry at Stockton State College in Pomona, New Jersey.

 


Luís Almeida

Assistant Professor at Faculty of Pharmacy, University of Coimbra and Principal Investigator and head of Molecular Therapy of Brain Disorders group at CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Portugal.

Luís Pereira de Almeida, is a tenured associate professor at Faculty of Pharmacy, University of Coimbra. His research is developed at CNC-Center for Neuroscience and Cell Biology, University of Coimbra Portugal where he is Principal Investigator and President. Luis also coordinates the Center for Innovative Biomedicine and Biotechnology (CIBB).
Luis did his PhD in the Gene Therapy Center of Lausanne, CHUV, Switzerland and spent short sabbatical leaves at CEA, France(2005), and at Massachussetts Institute of Technology (MIT-2010) and has been vice-president of the Portuguese Society for Stem Cells and Cell Therapy (2013-2015). 
Luis leads a talented research group focused on gene and stem cell therapy approaches for brain disorders, particularly Machado-Joseph disease/spinocerebellar ataxia type 3. He has published over 100 papers/book chapters (h-factor=41). Luis mentored 12 pos doctoral fellows and 17 PhD students and coordinated over 26 research projects, such as the transnational projects Synspread and ModelPolyQ within the European Joint Programme for Neurodegenerative Diseases (JPND), and presently including ViraVector - a Research Infrastructure for production and experimentation with viral vectors that integrates the national roadmap of scientific infrastructures.


 


Aurélie Goyenvalle

Group Leader in the Unit of Therapies for Neuromuscular Diseases at Université de Versailles St- Quentin U1179 INSERM, France

Dr Aurélie Goyenvalle is directing a research group at the University of Versailles focused on gene and antisense therapies for the treatment of neuromuscular disorders. Aurelie received her PhD in Virology at the University of Paris VII in 2006 from her work at Genethon in France, where she developed an exon-skipping gene therapy strategy for Duchenne muscular dystrophy (DMD) using adeno-associated virus vectors (AAV) encoding chimeric U7snRNA constructs carrying antisense sequences. To pursue her interest in gene therapy and splicing modulation approaches for DMD, she joined Prof. Kay Davies’ laboratory at the University of Oxford as a post-doctoral scientist supported by an EMBO fellowship. During her postdoc in Oxford and subsequent position at the Medical Research Council (MRC), Aurélie developed various splicing modulation approaches including the optimization of the U7 snRNA system for neuromuscular and neurodegenerative diseases and the evaluation of peptide-conjugated antisense oligonucleotides. In 2011, she joined the Institute of Myology in Paris to investigate splice switching approaches using novel antisense oligonucleotides and in 2012, she was awarded a Chair of Excellence program to establish her own group at the University of Versailles to develop novel RNA based technology for the treatment of neuromuscular diseases. In this context, she has notably demonstrated the therapeutic potential of a novel class of AONs made of tricyclo-DNA (tcDNA), which displays unique pharmacological properties and unprecedented uptake in many tissues after systemic administration. In 2015, Aurélie has been appointed a permanent research scientist position by the French national institute for health and medical research (INSERM) to pursue this line of research and she is currently head of a team evaluating splice-switching approach for various genetic disorders.

 


Lourdes Ruiz Desviat

Associate Professor at the Department of Molecular Biology, University Autonoma of Madrid; Director of the research institute “Centro de Biología Molecular Severo Ochoa”, Madrid, Spain. Group leader in the research line “Physiopathology studies and therapeutical approaches in animal and cellular models of neurometabolic diseases”.

Dr. Lourdes R Desviat is an Associate Professor at the Department of Molecular Biology, University Autonoma of Madrid. She is a group leader in the research line “Physiopathology studies and therapeutical approaches in animal and cellular models of neurometabolic diseases” and currently she is the Director of the research institute “Centro de Biología Molecular Severo Ochoa”, Madrid. Dr. Desviat and her research group have been working for several years in the field of inherited metabolic diseases. They focus mainly in organic acidemias and hyperphenylalaninemias, by generation and characterization of relevant animal and cellular models, to be used as research tools to understand the molecular and physiopathological mechanisms, to analyse potential biomarkers for prognosis and follow-up and to identify new therapeutical targets. Their ultimate aim is to develop and perform for many of the diseases under study preclinical studies of personalized RNA targeted therapies as well as pharmacological therapies with antioxidant compounds and mitochondrial activators. The research group has ample experience in the in vitro and in vivo use of antisense therapy to revert splicing defects in different rare diseases, participating in EU-COST Actions within this topic. To date, they have generated iPS cells derived from patients’ fibroblasts and differentiated them to neurons and cardiomyocytes as disease-relevant cell lineages. Now, they are using gene-editing CRISPR/Cas9 technology for the generation of cellular and animal models with specific splicing mutations, to identify and test candidate therapeutical antisense oligonucleotides.

Dr. Desviat is an author of more than 136 publications (with an h-index of 29 and 79 in Q1) and co-author of 16 book chapters. She has also supervised several Master (8) and PhD thesis (13).
 


Sónia Silva

Assistant Researcher at the Biofilm Research Lab, Dept. Biological Engineering, Univ. Minho, Braga

Sónia Silva received her graduation in Biology from Porto University in 2000 and in 2005 finished her Master in Molecular Genetics in the University of Minho (UM), in the field of yeasts metabolism and protein purification. Sónia Silva finished her PhD in Biomedical Engineering in 2006 at the Center of Biological Engineering (CEB)-UM and at Cardiff University (UK). Her PhD focused on characterization of Candida spp virulence factors and antifungal resistance. Since 2013, Sónia Silva have been working as Assistant Researcher at CEB-UM and her research focus in two main research lines: i) identification of molecular mechanisms underlying Candida virulence and antifungal resistance; ii) exploration of NAMs technology to control Candida spp virulence and antifungal resistance. She is authored of 76 original papers, 10 book chapters and 1 book, with over of 3600 citations and with H-index of 29. Sónia Silva registered 2 patents and supervised 4 PhD, 8 MSc and 3 graduation students. She is managed 4 competitive national and international research projects all in the field of Candida infections. 

 


Teresa Coelho

Neurologist and Neurophysiologist, Andrade’s Unit for Familial Amyloidosis, Santo Antonio Hospital, Centro Hospitalar Universitário do Porto

Teresa Coelho, MD, PhD. is a Neurologist and Neurophysiologist at Santo António Hospital, Centro Hospitalar Universitário do Porto, where clinical investigation led to the first description of familial amyloid polyneuropathy (FAP), published in Brain in 1952. 
Since 1997 Dr. Coelho has been head of Andrade’s Unit for Familial Amyloidosis at Centro Hospitalar Universitário do Porto. This Unit is an outpatient multidisciplinary clinic and is a reference centre for this disease. The hospital’s historical register includes about 3,000 observed subjects from 650 families. More than 1000 subjects are observed every year including 70 newly diagnosed subjects.
Dr. Coelho is also coordinator of the neuromuscular outpatient clinic and principal investigator of several pivotal clinical trials in transthyretin FAP, including those testing and leading to the approval of a siRNA and an ansisense oligonucleotide for the treatment of ATTR amyloidosis.

 

 

Abstract Submission

Authors are invited to submit abstracts for a virtual poster presentation. In the virtual poster sessions, besides the regular digital poster we will also encourage (optional) presenters to upload a short video presentation of their poster that can help to present the work in the most efficient way (detailed instructions will be sent later).

 

Abstracts should be structured according to the template, under the headings below:

Title
Title should be in bold Times New Roman font (font size: 14; 1pt spacing between lines).

Authors
Type initials and surnames of the authors (Times New Roman; font size:12; centred; 1pt spacing between lines). Underline the name of the presenting author. Include superscripted letters by alphabetical order referring to the affiliations.

Affiliation
This should include the name of department or laboratory, followed by the name of the organisation (university/company), city and country (Times New Roman; font size:10; justified; 1pt spacing between lines and 6pt spacing between paragraphs). One affiliation per line.

Abstract body
This should be in Times New Roman font (font size: 12; justified; 1pt spacing between lines and 6pt spacing between paragraphs). Abstract must be structured as: introduction, materials and methods, results, conclusions.

Graphs and tables are optional.

References (if necessary)
Along the text the references should be numbered and in between square brackets. In the references list they should be in Times New Roman font (font size: 11; justified; 1pt spacing between lines) and in Vancouver style.

Acknowledgements (if necessary)
This should be in Times New Roman font (font size: 11; justified; 1pt spacing between lines). Include the title in bold.

Additional Rules
The margins should be set to (sup.: 2,5cm; Inf.: 2.5cm; Left.: 2.5cm; Right.: 1.5cm). Abstract length is limited to one page A4, including tables and graphs, and all of the topics above.

Abstract submission deadline: 10th May 2021
Communication of abstracts results: 24th May 2021 

Deadline for submission of the work for the virtual poster presentation: 21st June 2021 
 

Registration

Fees:
- Undergraduate, MSc, PhD Student: 20€
- Academia/Clinicians: 20€
- Industry/Non-Academia: 50€

Deadline for registration and payment of participants with submitted abstracts: 7th June 2021 
Deadline for registration and payment of participants without abstracts: 25th June 2021

Sponsors

CO-ORGANIZED BY: 

 


SUPPORTED BY:

  

European Union’s Horizon 2020 research and innovation programme under grant agreement No 810685


PLATINUM SPONSORS 


Contact: pedro.moreno@ineb.up.pt


More information:
Events Management Unit | Rua Alfredo Allen 208 | 4200-135 Porto, Portugal
Email: events@i3s.up.pt | Tel: +351 226 074 900